Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Brain Neoplasms
  • Camptothecin
  • Carcinoma, Non-Small-Cell Lung
  • Dacarbazine
  • Lung Neoplasms

abstract

  • Second-line treatment with temozolomide and irinotecan showed tolerable toxicities. The response rates, median survival times, and 1-year survival rates were comparable to other active NSCLC agents.

publication date

  • March 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 17409864

Additional Document Info

start page

  • 245

end page

  • 51

volume

  • 1

number

  • 3